Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on March 12, 2026. The filing discloses a material change in executive leadership, specifically the appointment of an Interim Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial information disclosed relates to the compensation package for the newly appointed Interim CFO:
- Monthly Salary: $50,000
- Initial Equity Grant: 10,000 Restricted Stock Units (RSUs) vesting on June 30, 2026
- Contingent Equity Grant: Additional 2,500 RSUs if serving as Interim CFO on July 1, 2026
Material Changes
The primary material change reported is the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Mr. Ramsay is a former CFO of the Company (serving from 2003–2009 and 2013–2015) and brings extensive experience in the biopharmaceutical sector, including prior roles at Bonti, Inc., Savara Inc., and Exuma Biotech, Inc.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the new executive appointment. The text does not provide a clear value for any operational risks or unusual items.
Investor Verification Checklist
- Verify the effective date of the Interim CFO appointment (March 23, 2026).
- Confirm the vesting schedule and holding period requirements for the 10,000 initial RSUs and the contingent 2,500 RSUs.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that this filing does not contain updated financial statements or liquidity metrics.